Trial reportPloS one2026
Glabridin content and metabolic effects of liquorice confectionaries: A secondary analysis of a randomized crossover trial in young adults.
Trial report in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLiquorice, a popular confectionary product, contains several bioactive compounds. Amongst them, glycyrrhizic acid is associated with increased blood pressure, and glabridin is associated with anti-inflammatory and glucose-lowering effects. The aim was to assess the association between short term liquorice intake at a dose known to elevate blood pressure, and markers of dysglycemia, blood lipids, high-sensitivity C-reactive protein (hsCRP), and calcium metabolism.
methodsIn a 2x2 crossover study, 28 healthy adults were randomized to consume liquorice or a control product in alternating 2-week periods, with measurements of blood glycated haemoglobin A1c as well as plasma glucose, calcium ion, parathyroid hormone, and lipids at the end of each period. Liquorice glabridin content was determined via LC-MSMS analysis.
resultsThe liquorice contained 0.25 ± 0.14 µg glabridin per mg. The plasma hsCRP value increased by 32.5% (95% CI -9.7 to 74.6) during the intervention period vs 311.5% (95% CI -40.8 to 663.7) during the control period, P = .045. No effects on the other markers were observed.
conclusionLiquorice intake did not improve metabolic markers but attenuated hsCRP elevation. The potential metabolic benefits of glabridin are unlikely to outweigh the hypertensive effects when consumed as whole liquorice.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.